Intermountain Healthcare, based in Salt Lake City, has established a genomics research and testing company called Navican Genomics.
Using a sequencing test developed at Intermountain Healthcare, Navican Genomics will use precision medicine to identify individual mutations within cancer tumors. This ability to target mutations will help oncologists determine personalized cancer prevention and treatment options for patients.
Ingo Chakravarty, CEO and president of Navican Genomics, will lead a team in collaboration with physicians, pharmaceutical companies and other healthcare stakeholders to find treatments and clinical trials for patients.